Bone Biologics Corp: management transactions · United States · SEC (Form 4)

About Bone Biologics Corp

Bone Biologics Corp is a U.S.-based company listed on the NASDAQ market in the United States, focused on orthobiologic products for spinal fusion and broader bone-regeneration applications. For French-speaking investors, it should be viewed as a small-cap biotech/medtech name with a development-stage profile rather than a mature commercial healthcare company. The company’s core scientific platform is centered on the NELL-1 protein and its lead candidate NB1, which is designed to provide targeted, guided control of bone regeneration in surgical settings. ([bonebiologics.com](https://www.bonebiologics.com/news-events/bone-biologics-regains-compliance-with-nasdaq-continued-listing-requirements-2/?utm_source=openai)) Bone Biologics traces its origins to 2004, when the underlying technology was developed by University of California professors in collaboration with an Osaka University professor and a University of Southern California surgeon. The current public company structure came later, through a reverse merger completed in 2014, after which the entity was renamed Bone Biologics Corp. The company is incorporated in Delaware and reports its headquarters in Burlington, Massachusetts. This history is typical of a public biotech platform company built around intellectual property, preclinical validation, and a staged path toward clinical development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1419554/000149315215001120/form10-k.htm?utm_source=openai)) Operationally, Bone Biologics is focused on orthobiologics, meaning biological products intended to stimulate new bone formation. Its primary commercial target is the spinal fusion market, a large but highly regulated segment where clinical evidence, safety, and reimbursement dynamics are critical. Management also references possible applications beyond spine surgery, including orthopedics, neurosurgery, plastic reconstruction, interventional radiology, and sports medicine. Even so, the company’s strategic emphasis remains concentrated on spine-related bone regeneration. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1419554/000149315215001120/form10-k.htm?utm_source=openai)) From a competitive standpoint, Bone Biologics occupies a highly specialized niche against much larger medical-device and biomaterials companies with deeper sales infrastructure and broader product portfolios. Its differentiation lies less in scale and more in its science, intellectual property, and the potential of its NELL-1-based approach to offer a more targeted bone-growth mechanism. As a development-stage company, it remains dependent on external financing and on the successful progression of clinical and regulatory milestones. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1419554/000149315215001120/form10-k.htm?utm_source=openai)) Recent news has been material. In January 2026, the company published a summary of key corporate, scientific, and operational milestones achieved in 2025 and outlined its strategic outlook for 2026. In June 2025, Bone Biologics announced that it had regained compliance with Nasdaq’s minimum bid price requirement, allowing it to remain listed on the Nasdaq Capital Market. Around the same period, it also filed a patent application for its bone regeneration technology and completed a public financing transaction. For investors, the equity case remains tied to clinical execution, intellectual-property progress, funding needs, and dilution risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1419554/000149315226000896/ex99-1.htm?utm_source=openai))